北京诺诚健华医药科技有限公司 Innocare
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
InnoCare Announces Approval of Clinical Trial of TYK2 JH2 Allosteric Inhibitor ICP-488 in China 2022-03-28 10:48
InnoCare Releases 2021 Annual Results and Business Highlights 2022-03-23 08:08
InnoCare Announces Acceptance of Supplemental New Drug Application for Orelabrutinib in Relapsed or Refractory Waldenström's Macroglobulinemia in China 2022-03-14 08:30
InnoCare Announces Approval of Phase II Clinical Trial Using Orelabrutinib for the Treatment of NMOSD in China 2022-03-02 10:37
InnoCare Announces Dosing of First Patient in Phase II Clinical Trial Using Orelabrutinib for the Treatment of ITP 2022-02-22 17:09
InnoCare and Keymed Jointly Announce Dosing of First Patient in Clinical Trial of CD20xCD3 Bispecific Antibody CM355 2022-01-18 14:51
InnoCare to Attend Upcoming Investor Conferences to Share Latest Company Development 2022-01-07 08:30
Orelabrutinib Data Presented at the 63rd Annual Meeting of ASH 2021-12-14 12:50
InnoCare Announces Inclusion of Orelabrutinib in China National Reimbursement Drug List 2021-12-03 10:13
InnoCare Announces the Clearance of Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 by U.S. FDA 2021-11-15 08:30
InnoCare to Attend Upcoming Investor Conferences to Share Latest Company Development 2021-11-12 14:14
InnoCare to Present Orelabrutinib Data at the Upcoming 63rd Annual Meeting of ASH 2021-11-09 13:06
InnoCare Announces Approval of Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 in China 2021-10-19 12:56
InnoCare and Keymed Jointly Announce Approval of Clinical Trial of CD20xCD3 Bispecific Antibody CM355 2021-09-17 20:00
InnoCare Announces Clearance by U.S. FDA of Clinical Trial of pan-TRK Inhibitor ICP-723 2021-08-31 08:30
InnoCare Releases 2021 Half Year Results and Business Highlights 2021-08-29 19:49
InnoCare Announces First Subject Dosed in Clinical Trial of ICP-332 2021-08-16 09:32
InnoCare Announces Approval of Phase II Clinical Trial Using Orelabrutinib for the Treatment of ITP in China 2021-08-11 08:00
InnoCare Announces Breakthrough Therapy Designation of Orelabrutinib by US FDA for Treatment of R/R MCL 2021-06-28 16:02
InnoCare Announces Approval of Initiation of Phase 1 Clinical Trial of RTK Inhibitor ICP-033 in China 2021-06-25 19:04
1 2